Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bdtx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Black Diamond Therapeutics, Inc. (BDTX) measures how much investors pay for each dollar of the company's trailing earnings. BDTX's current PE ratio of N/A is calculated by dividing its stock price of $1.92 by its TTM earnings per share of -$0.75.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Black Diamond Therapeutics, Inc.You BDTX | $110M | N/A | — | -$0.75 |
 Aardvark Therapeutics, Inc. Common Stock AARD | $79M | N/A | — | -$2.64 |
 Abeona Therapeutics Inc. ABEO | $309M | 3.92x | — | $1.34 |
 Avalo Therapeutics, Inc. AVTX | $147M | N/A | — | -$5.84 |
 Caribou Biosciences, Inc. CRBU | $185M | N/A | — | -$1.59 |
 Enanta Pharmaceuticals, Inc. ENTA | $255M | N/A | — | -$3.84 |
 Fennec Pharmaceuticals Inc. FENC | $252M | N/A | — | -$0.34 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 6.18x | $0.39 | — | |
2024-12-31 FY2024 | — | $-1.27 | — | |
2023-12-31 FY2023 | — | $-1.88 | — | |
2022-12-31 FY2022 | — | $-2.52 | — | |
2021-12-31 FY2021 | — | $-3.47 | — | |
2020-12-31 FY2020 | — | $-2.04 | — | |
2019-12-31 FY2019 | — | $-0.98 | — | |
2018-12-31 FY2018 | — | $-0.64 | — | |
2017-12-31 FY2017 | — | $-0.64 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Black Diamond Therapeutics, Inc. (BDTX) measures how much investors pay for each dollar of the company's trailing earnings. BDTX's current PE ratio of N/A is calculated by dividing its stock price of $1.92 by its TTM earnings per share of -$0.75.
Frequently asked questions
BDTX pe ratio · 6 questionsBDTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.92 and TTM EPS of -$0.75. Data sourced from Financial Modeling Prep via BDTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Black Diamond Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08